Join

Compare · CI vs VRDN

CI vs VRDN

Side-by-side comparison of The Cigna Group (CI) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CI and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • CI is the larger of the two at $75.14B, about 42.9x VRDN ($1.75B).
  • CI has been more active in the news (18 items in the past 4 weeks vs 15 for VRDN).
  • Both have 25 recent analyst ratings on file.
MetricCIVRDN
Company
The Cigna Group
Viridian Therapeutics Inc.
Price
$286.00+0.71%
$16.59-2.38%
Market cap
$75.14B
$1.75B
1M return
-
+7.90%
1Y return
-
+29.95%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2014
News (4w)
18
15
Recent ratings
25
25
CI

The Cigna Group

Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

VRDN

Viridian Therapeutics Inc.

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Latest CI

Latest VRDN